Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial
Merck Sharp & Dohme LLC
Amy E Colson; Anthony M Mills; Moti N Ramgopal; Christopher Bettacchi; Olayemi O Osiyemi; Federico Hinestrosa; Gordon Crofoot; Harold P Katner; Hiroyuki Gatanaga; Margaret Johnson; Tracy L Diamond; Erika Barninger; Karen Eves; Feng-Hsiu Su; Yayun Xu; Stephanie O Klopfer; Luisa M Stamm; Michelle C Fox; Rima Lahoulou